BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 33216879)

  • 1. Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension.
    Brook RD; Kaciroti N; Bakris G; Dahlöf B; Pitt B; Velazquez E; Weber MA; Jamerson KA
    Am J Hypertens; 2021 May; 34(5):531-539. PubMed ID: 33216879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients.
    Brook RD; Kaciroti N; Bakris G; Dahlöf B; Pitt B; Velazquez E; Weber M; Zappe DH; Hau T; Jamerson KA
    J Am Heart Assoc; 2018 Jan; 7(1):. PubMed ID: 29301757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
    Jamerson K; Weber MA; Bakris GL; Dahlöf B; Pitt B; Shi V; Hester A; Gupte J; Gatlin M; Velazquez EJ;
    N Engl J Med; 2008 Dec; 359(23):2417-28. PubMed ID: 19052124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers.
    Bakris GL; Cooper-Dehoff RM; Zhou Q; Kupfer S; Champion A; Pepine CJ;
    Am J Cardiovasc Drugs; 2007; 7 Suppl 1():25-9. PubMed ID: 19845074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.
    Jamerson KA; Nwose O; Jean-Louis L; Schofield L; Purkayastha D; Baron M
    Am J Hypertens; 2004 Jun; 17(6):495-501. PubMed ID: 15177521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which is the optimal antihypertensive combination in different diseases, a renin- angiotensin-aldosterone system inhibitor with a diuretic or with a calcium channel blocker?
    Riva N; Lip GY
    Curr Pharm Des; 2013; 19(21):3753-65. PubMed ID: 23286431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin System Blockade Combined With Calcium Channel Blockers Is Superior to Other Combinations in Cardiovascular Protection With Similar Blood Pressure Reduction: A Meta-Analysis in 20,451 Hypertensive Patients.
    Chi C; Tai C; Bai B; Yu S; Karamanou M; Wang J; Protogerou A; Blacher J; Safar ME; Zhang Y; Xu Y
    J Clin Hypertens (Greenwich); 2016 Aug; 18(8):801-8. PubMed ID: 26778747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate.
    Kereiakes DJ; Neutel JM; Punzi HA; Xu J; Lipka LJ; Dubiel R
    Am J Cardiovasc Drugs; 2007; 7(5):361-72. PubMed ID: 17953475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.
    da Silva PM
    Clin Drug Investig; 2010; 30(9):625-41. PubMed ID: 20626210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective randomized study of the tolerability and efficacy of combination therapy for hypertensive chronic kidney disease: results of the PROTECT-CKD study.
    Hayashi M; Uchida S; Kawamura T; Kuwahara M; Nangaku M; Iino Y;
    Clin Exp Nephrol; 2015 Oct; 19(5):925-32. PubMed ID: 25680887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
    Bakris GL; Sarafidis PA; Weir MR; Dahlöf B; Pitt B; Jamerson K; Velazquez EJ; Staikos-Byrne L; Kelly RY; Shi V; Chiang YT; Weber MA;
    Lancet; 2010 Apr; 375(9721):1173-81. PubMed ID: 20170948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure.
    Asayama K; Ohkubo T; Metoki H; Obara T; Inoue R; Kikuya M; Thijs L; Staessen JA; Imai Y;
    Hypertens Res; 2012 Nov; 35(11):1102-10. PubMed ID: 22895063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular events during differing hypertension therapies in patients with diabetes.
    Weber MA; Bakris GL; Jamerson K; Weir M; Kjeldsen SE; Devereux RB; Velazquez EJ; Dahlöf B; Kelly RY; Hua TA; Hester A; Pitt B;
    J Am Coll Cardiol; 2010 Jun; 56(1):77-85. PubMed ID: 20620720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
    Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
    Pepine CJ; Handberg EM; Cooper-DeHoff RM; Marks RG; Kowey P; Messerli FH; Mancia G; Cangiano JL; Garcia-Barreto D; Keltai M; Erdine S; Bristol HA; Kolb HR; Bakris GL; Cohen JD; Parmley WW;
    JAMA; 2003 Dec; 290(21):2805-16. PubMed ID: 14657064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    JAMA; 2002 Dec; 288(23):2981-97. PubMed ID: 12479763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ.
    Duprez D; Ferdinand K; Purkayastha D; Samuel R; Wright R
    Vasc Health Risk Manag; 2011; 7():701-8. PubMed ID: 22174580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
    Evid Based Child Health; 2014 Sep; 9(3):498-580. PubMed ID: 25236305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of benazepril monotherapy to amlodipine plus benazepril in the treatment of patients with mild and moderate hypertension: a multicentre, randomized, double-blind, parallel-controlled study].
    Fan CM; Yan LR; Tao YK; Wang L; Li YQ; Gao MM; Wang YN; Li CX; Wang XW; Lu XL; Pang HM; Li YS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Jan; 39(1):57-60. PubMed ID: 21418799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benazepril combined with either amlodipine or hydrochlorothiazide is more effective than monotherapy for blood pressure control and prevention of end-organ injury in hypertensive Dahl rats.
    Zhou MS; Jaimes EA; Raij L
    J Cardiovasc Pharmacol; 2006 Jul; 48(1):857-61. PubMed ID: 16891915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.